Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered serious bleeding events. Pharmaceutical firms, including the makers of Xarelto, possess a duty to ensure that their drugs are reasonably secure for use – and failure to perform so could be grounds for compensation. Our lawyers are working challenging to get these hurt by the drug the compensation they’re entitled to.
Whilst bleeding is a frequent complication related with anticoagulants, it has been alleged that Xarelto is xarelto an nsaid a lot more unsafe than classic blood thinners due to the fact no antidote exists to reverse its blood-thinning effects. This signifies that, in the event of an emergency, individuals might be at threat for irreversible bleeding issues, such as life-threatening internal and gastrointestinal hemorrhaging.
In the event you or possibly a loved a single suffered a significant bleeding event following taking Xarelto, you may have legal recourse. For much more details, make contact with us today to have your case reviewed, cost-free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are looking for compensation from Bayer and Janssen for previous and future healthcare bills, lost wages, pain and suffering and, in circumstances of death, funeral costs. Furthermore, they are in search of punitive damages, which are generally awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is harmful and defective. The plaintiffs claim that, unlike conventional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective implies of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs in the lawsuits allege significant and fatal injuries, like cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user in the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing hazardous clotting.
Visit this page for much more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.